Claims for Patent: 10,342,788

Summary for Patent: 10,342,788

Title:	1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
Abstract:	Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer\'s disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases. ##STR00001##
Inventor(s):	Hood; John (San Diego, CA), KC; Sunil Kumar (San Diego, CA), Wallace; David Mark (San Diego, CA)
Assignee:	Samumed, LLC (San Diego, CA)
Application Number:	16/032,905
Patent Claims:	1. A compound which is ##STR01221## or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound which is ##STR01222## or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 3. The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable excipient is selected from the group consisting of: water, a surfactant, an acid, a sugar alcohol, and mixtures thereof. 4. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is selected from the group consisting of: sterile water, tyloxapol, hydrochloric acid, a sugar alcohol, and mixtures thereof. 5. The pharmaceutical composition of claim 2, wherein the composition is a liquid composition. 6. The pharmaceutical composition of claim 2, wherein the composition is an emulsion. 7. The pharmaceutical composition of claim 2, wherein the composition is a colloidal solution. 8. The pharmaceutical composition of claim 2, wherein the composition is formulated for respiratory delivery. 9. A colloidal composition comprising a compound which is ##STR01223## or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 10. The colloidal composition of claim 9, wherein the pharmaceutically acceptable excipient is selected from the group consisting of: water, a surfactant, an acid, a sugar alcohol, and mixtures thereof. 11. The colloidal composition of claim 10, wherein the pharmaceutically acceptable excipient is selected from the group consisting of: sterile water, tyloxapol, hydrochloric acid, a sugar alcohol, and mixtures thereof. 12. The colloidal composition of claim 9, wherein the composition is formulated for respiratory administration. 13. The respiratory administration of claim 12, wherein the administration is combined with one or more of pirfenidone, prednisone, azathioprine, N-acetylcysteine, interferon-.gamma. 1b, bosentan or an anti-inflammatory agent. 14. A method of treating pulmonary fibrosis in a mammal, comprising administering via inhalation to the mammal a therapeutically effective amount of a compound, having the structure of: ##STR01224## or a pharmaceutically acceptable salt thereof. 15. A method of treating pulmonary fibrosis in a mammal, comprising administering via inhalation to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a compound, having the structure of: ##STR01225## or a pharmaceutically acceptable salt thereof. 16. The method of claim 14, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). 17. The method of claim 14, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). 18. The method of claim 14, wherein the mammal is a human. 19. The method of claim 15, wherein the mammal is a human.

Details for Patent 10,342,788

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2032-05-04